Gastric Cancer Treatment Drugs, Pipeline Insights, and Companies 2024

DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Gastric Cancer Pipeline Report
• In September 2024:- Ono Pharmaceutical- This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).
• In September 2024:- AstraZeneca- This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
• DelveInsight's Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment.
• The leading Gastric Cancer Companies such as Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
• Promising Gastric Cancer Therapies such as Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.

Explore our comprehensive Gastric Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Gastric Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastric Cancer Overview
Gastric cancer, also known as stomach cancer, is a formidable adversary in the realm of oncology, characterized by the malignant growth of cells lining the stomach. This disease poses a significant global health burden, with varying incidence rates across different regions and populations. Gastric cancer often manifests silently, with symptoms appearing in advanced stages, making early detection and intervention crucial for successful treatment outcomes. Risk factors such as Helicobacter pylori infection, tobacco use, certain dietary habits, and genetic predisposition play pivotal roles in its development.

Gastric Cancer Emerging Drugs Profile
• Catumaxomab: Linton Pharm Co. Ltd.
Catumaxomab is a bispecific monoclonal antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects. It is co-developed by Trion Pharma and Neovii Biotech. Currently it is in Phase III stage of clinical trial evaluation to treat Gastric Cancer.
• HLX10: Shanghai Henlius Biotech
HLX10, a novel recombinant humanized anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius. The drug candidate works on programmed cell death-1 receptor antagonists and T lymphocyte stimulant mechanism of action. Currently being evaluated in the Phase III studies.
• FLX475: RAPT Therapeutics
FLX475 is an oral, small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. It is in collaboration agreement with Hanmi for specific regions like Korea, Taiwan and China. Currently the drug is being evaluated in Phase II for the treatment of Gastric Cancer.
• Savolitinib: AstraZeneca/HUTCHMED
Savolitinib is an oral, potent and highly selective MET tryokinase inhibitors (TKI). It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. The drug is been developed under global licensing and collaboration agreement with AstraZeneca. The drug is in Phase II stage of clinical trials.
• ASP 2138: Astellas Pharma
ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology. The drug is under clinical development by Xencor and currently drug is in Phase I stage of clinical trials for the treatment of gastric cancer.
• Minnelide : Minneamrita Therapeutics LLC
Minnelide is under clinical development by Minneamrita Therapeutics. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). Currently being investigated in a Phase I clinical trial in patients suffering with gastric cancer.

Dive into our Gastric Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Gastric Cancer Treatment Therapies- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastric Cancer Therapeutics Assessment
There are approx. 180+ key companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.

DelveInsight's Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Download the Gastric Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Gastric Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Gastric Cancer Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Dive into our detailed Gastric Cancer Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Gastric Cancer Products, Companies, and Unmet Needs- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastric Cancer Pipeline Report
• Coverage- Global
• Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
• Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.

Gain valuable insights into emerging therapies and innovations with our Gastric Cancer Pipeline Report @ Gastric Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr a

Table of Content
1. Introduction
2. Executive Summary
3. Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Catumaxomab : Neovii Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. FLX475: RAPT Therapeutics
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. ASP 2138: Astellas Pharma
15. Inactive Products
16. Gastric Cancer Key Companies
17. Gastric Cancer Key Products
18. Gastric Cancer - Unmet Needs
19. Gastric Cancer - Market Drivers and Barriers
20. Gastric Cancer - Future Perspectives and Conclusion
21. Gastric Cancer Analyst Views
22. Gastric Cancer Key Companies
23. Appendix

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas

This release was published on openPR.